Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 26, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 28, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-436441
Filed / recorded
Oct 28, 2026, 9:38 PM UTC
Added to OQRO
Oct 28, 2026, 9:40 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
CRISPR Therapeutics AG
Issuer CIK
1674416
Ticker
CRSP
Reporting person
Samarth Kulkarni
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Oct 26, 2026
Transaction code
A
Shares / units
57,500
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
57,500
Ownership form
Direct
Amendment
No
Footnotes from the filing
This option was granted on October 26, 2026 with respect to 57,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.